BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 11472274)

  • 1. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control.
    Pratley RE; Foley JE; Dunning BE
    Curr Pharm Des; 2001 Sep; 7(14):1375-97. PubMed ID: 11472274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.
    McLeod JF
    Clin Pharmacokinet; 2004; 43(2):97-120. PubMed ID: 14748619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meglitinide analogues in the treatment of type 2 diabetes mellitus.
    Landgraf R
    Drugs Aging; 2000 Nov; 17(5):411-25. PubMed ID: 11190420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
    Malaisse WJ
    Treat Endocrinol; 2003; 2(6):401-14. PubMed ID: 15981944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia.
    Dunning BE; Deacon R; Gutierrez C; Paladini S; Valentin MA; Foley JE
    Diabetologia; 2003 Mar; 46 Suppl 1():M22-9. PubMed ID: 12652355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulinotropic meglitinide analogues.
    Dornhorst A
    Lancet; 2001 Nov; 358(9294):1709-16. PubMed ID: 11728565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].
    Li JW; Tian HM; Yu HL; Zhang XX; Zhao GZ; Wang JN
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):267-70. PubMed ID: 15807285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
    Kikuchi M
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide.
    Hu S; Wang S; Dunning BE
    Int J Exp Diabetes Res; 2001; 2(1):63-72. PubMed ID: 12369728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
    Scheen AJ
    Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.
    Kalbag JB; Walter YH; Nedelman JR; McLeod JF
    Diabetes Care; 2001 Jan; 24(1):73-7. PubMed ID: 11194245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
    Owens DR
    Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
    Hanefeld M; Bouter KP; Dickinson S; Guitard C
    Diabetes Care; 2000 Feb; 23(2):202-7. PubMed ID: 10868832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological properties of nateglinide, rapid-onset/short-duration insulinotropic agent, in the treatment of type 2 diabetes].
    Ikenoue T; Kondo N
    Nihon Yakurigaku Zasshi; 2000 Sep; 116(3):171-80. PubMed ID: 11031747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
    Raskin P; Klaff L; McGill J; South SA; Hollander P; Khutoryansky N; Hale PM;
    Diabetes Care; 2003 Jul; 26(7):2063-8. PubMed ID: 12832314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial.
    Li J; Tian H; Li Q; Wang N; Wu T; Liu Y; Ni Z; Yu H; Liang J; Luo R; Li Y; Huang L
    Diabetes Obes Metab; 2007 Jul; 9(4):558-65. PubMed ID: 17587398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meglitinide analogues for type 2 diabetes mellitus.
    Black C; Donnelly P; McIntyre L; Royle PL; Shepherd JP; Thomas S
    Cochrane Database Syst Rev; 2007 Apr; 2007(2):CD004654. PubMed ID: 17443551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.
    Keilson L; Mather S; Walter YH; Subramanian S; McLeod JF
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1081-6. PubMed ID: 10720043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
    Drug Ther Bull; 2003 Jul; 41(7):52-4. PubMed ID: 12879789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.